Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 12:7:e09.
doi: 10.15420/cfr.2020.33. eCollection 2021 Mar.

Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab

Affiliations
Review

Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab

Ava Diarra et al. Card Fail Rev. .

Abstract

Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses - in particular, the Coxsackie B viruses - are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.

Keywords: Devic’s syndrome; enterovirus; myocarditis; rituximab.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to declare.

References

    1. Patterson SL, Goglin SE. Neuromyelitis optica. Rheum Dis Clin N Am. 2017;43:579–91. doi: 10.1177/1352458513495939. - DOI - PubMed
    1. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–73. doi: 10.1016/j.ctrv.2005.05.007. - DOI - PubMed
    1. Fairley CK, Ryan M, Wall PG et al. The organisms reported to cause myocarditis and pericarditis in England and Wales. J Infect. 1996;32:223–5. doi: 10.1016/s0163-4453(96)80023-5. - DOI - PubMed
    1. Sellier-Leclerc A-L, Belli E, Guérin V et al. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol. 2013;28:1875–9. doi: 10.1007/s00467-013-2485-9. - DOI - PubMed
    1. Alonso JJ, Cánovas A, Rubio G. Lethal enterovirus myocarditis associated with rituximab and chemotherapy for follicular lymphoma. Med Clínica (Barc) 2013;141:459–60. doi: 10.1016/j.medcli.2013.03.001. [in Spanish]. - DOI - PubMed

LinkOut - more resources